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Diverse chemokines and their receptors have been associated with tumor growth, tumor dissemination, and local immune escape.
In diﬀerent tumor entities, the level of chemokine receptor CXCR4 expression has been linked with tumor progression and
decreased survival. The aim of this study was to evaluate the inﬂuence of CXCR4 expression on the progression of human renal
cell carcinoma. CXCR4 expression of renal cell carcinoma was assessed by immunohistochemistry in 113 patients. Intensity of
CXCR4 expression was correlated with both tumor and patient characteristics. Human renal cell carcinoma revealed variable
intensities of CXCR4 expression. Strong CXCR4 expression of renal cell carcinoma was signiﬁcantly associated with advanced T-
status (P = .039), tumor dediﬀerentiation (P = .0005), and low hemoglobin (P = .039). In summary, strong CXCR4 expression
was signiﬁcantly associated with advanced dediﬀerentiated renal cell carcinoma.
Copyright © 2008 Thomas C. Wehler et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Renal cell carcinoma (RCC) is the sixth leading cause of
cancer-related deaths in the Western world and comprises 2-
3% of all newly diagnosed malignancies in adults. Among
the diﬀerent kidney neoplasms, it represents with 85% the
largest fraction [1]. The age-adjusted incidence of RCC
in Western nations is 5–12/100000 in women or men,
respectively, with a peak incidence in the 6th decade [2].
In practice, the only curable treatment is nephrectomy
performed in early stages of the disease. However, about
30–50% of patients have already metastases at presentation,
and approximately one third of the nephrectomized patients
relapse and progress with metastatic disease. The preferential
sites of metastasis are the regional lymph nodes, the lung,
the liver, and the bones. Survival strongly depends on the
tumor stage at presentation. The 5-year survival rate is
approximately 50%, whereas the median survival in case of
metastasis is less than one year [3–5]. The current standard
treatment for metastasized RCC consists of the application
of IFN-α and IL-2 [6]. Recently, phase II clinical trials
using receptor-tyrosine kinase (RTK) inhibitors have shown
more promising results and lead to approval by the Food
and Drug Administration (FDA) and European Medicines
Agency (EMEA) [2].
In vivo and in vitro results from diﬀerent tumor entities
suggestthatorgan-speciﬁcmetastasisispartiallygovernedby
interactions of chemokine receptors on cancer cells and their
corresponding chemokines expressed in target organs and
thetumorbed. Thisprocessisconsidered todirectlymphatic2 Journal of Oncology
and hematogenous spread and furthermore inﬂuences the
sites of metastatic growth [7]. Chemokines and their respec-
tive G-protein-coupled receptors were initially described to
mediate diﬀerent pro- and anti-inﬂammatory responses [8].
In particular, the high expression of stromal cell derived
factor 1α (SDF-1α), also known as CXCL12, by endothelial
cells, biliary epithelial cells, bone marrow stromal cells, and
lymph nodes results in a chemotactic gradient attracting
CXCR4 expressing lymphocytes into those organs [9–15].
Most recently, CXCR4 has shifted into focus as it is the most
common chemokine receptor expressed on cancer cells [16].
It was suggested to play an important role in tumor spread
of colorectal, breast, and oral squamous cell carcinoma as all
of them commonly metastasize to SDF-1α expressing organs
[17–20]. Data obtained from in vitro as well as from murine
in vivo models, analyzing the metastatic ability of CXCR4i n
expressing cancer cells, underlined the key role of CXCR4f o r
tumor cell malignancy, as activation of CXCR4b ySDF-1α
inducedmigration,invasion,andangiogenesisofcancercells
[21–23].
Therefore, we evaluated the expression of CXCR4i n
renal cancer cell lines and specimens and correlated these
results with the patients’ clinicopathological parameters and
survival.
2.MaterialsandMethods
2.1. Tissue Samples. Renal cell carcinoma samples were
intraoperatively obtained from 113 patients with renal clear
cell carcinoma who underwent surgery at the Department
of Urology of the University of Mainz. The morphological
classiﬁcation of the carcinomas was conducted according to
World Health Organization (WHO) speciﬁcations. Patients
were followed up on a regular basis depending on the
procedure performed.
2.2. Immunohistochemical Staining. The avidin-biotin-
complex method (LSAB+ System-HRP Kit, Dako
Cytomation, Hamburg, Germany) was used to detect the
protein CXCR4( a n t i - CXCR4, dilution 1 : 300; Capralogics
Inc., Mass, USA). Formalin-ﬁxed and paraﬃn-embedded
t i s s u e sw e r ed e p a r a ﬃnized and subsequently microwaved
(600W, 15 minutes) in citrate buﬀer (ph 6.0). After
preincubation with hydrogen peroxide (LSAB+ System-HRP
Kit, Dako Cytomation, Hamburg, Germany) and human
AB plasma (Department of Transfusion, University of
Mainz, Mainz, Germany), the primary antibodies were
applied for one hour at room temperature. After incubation
with the secondary antibody (LSAB+ System-HRP Kit,
Dako Cytomation, Hamburg, Germany), the avidin-biotin
complex was added and the enzyme activity was visualized
with diaminobenzidine (LSAB+ System-HRP Kit, Dako
Cytomation, Hamburg, Germany). Counterstaining was
performed with haematoxylin (Roth, Karlsruhe, Germany).
For negative controls only the secondary antibody was
used. A negative control was performed for each sample
(N = 113). For positive controls formalin-ﬁxed and
paraﬃn-embedded tissue samples of the human spleen were
applied.
2.3. Evaluation of Immunostaining. Immunostaining was
evaluated by three authors independently (T.C. Wehler, C.
Graf, S. Biesterfeld), blinded to patient outcome and all clin-
icopathologic ﬁndings. The immunohistochemical staining
was analyzed according to a scoring method as previously
validated and described [17]. The tumors were classiﬁed into
four groups based on the homogeneous staining intensity:
0, absent; 1, weak; 2, intermediate; 3, strong staining. In the
case of heterogeneous staining within the same sample, the
respective higher score was chosen, if more than 50% of cells
revealed a higher staining intensity. If expression intensity
was exactly in between two scores, the authors agreed on 0.5
point-steps. If evaluations did not agree, specimens were re-
evaluated and reclassiﬁed according to the assessment given
most frequently by the observers.
2.4. Statistics. The correlation of CXCR4 staining intensity
withclinicopathologicalpatternswasassessedwiththeχ2 test
and with the unpaired Student t-test (one/two sided), when
appropriate. Survival rates were visualized applying Kaplan-
Meiercurves,andP-valuesweredeterminedbylog-ranktest.
P<. 05 was considered signiﬁcant and P<. 001 highly
signiﬁcant in all statistical analyses.
3. Results
3.1. Tumor Characteristics and Patient Proﬁles. The selected
group of patients represents the typical characteristics of
renal cell carcinoma in industrialized countries.
3.2. Immunohistochemical Staining of CXCR4 in Renal Cell
Carcinoma. The staining of normal human kidney tissue
for CXCR4 revealed a cytoplasmatic expression and in only
few specimens an additional weak membranous location
of CXCR4 (see Figure 1). A nuclear staining of CXCR4
was not observed. In renal cell carcinoma, the respective
expression rate for CXCR4 was 100% (113/113) and varied
from weak (34%), intermediate (42%), to strong (24%).
Negative controls of human renal cancer remained negative
for all tissue samples (N = 113, not shown). Glomeruli
did not reveal any CXCR4 expression and thus served
as internal negative control. As internal positive control,
splenic lymphocytes (strong CXCR4 expression) and tubuli
cells (intermediate CXCR4 expression) were used. Similarly,
inﬂammatory inﬁltrates in kidney tissue (data not shown)
depicted a strong CXCR4 expression.
3.3. Relevance of CXCR4 Expression in Renal Cell Carcinoma.
Strong CXCR4 expression signiﬁcantly correlated with dedif-
ferentiated (P = .0005) and progressed renal cell carcinoma,
indicated by T-status (P = .039; see Table 1). Furthermore,
strong CXCR4 expression revealed a signiﬁcant association
with low hemoglobin values (P = .039) and a nonsigniﬁcant
trend towards increased thrombocytes (P = .089/P = .18,Journal of Oncology 3
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tubuli did reveal a medium-strong predominantly cytoplasmic CXCR4 expression. All cancer samples did reveal a cytoplasmatic expression
of CXCR4 ranging from weak (34%) to medium (42%) and strong (24%).
resp.). No correlation was seen for age, size, survival, or
creatinine values.
4. Discussion
The expression of the chemokine receptor CXCR4h a sb e e n
reportedinvariousepithelial,mesenchymal,andhematopoi-
etic tumors. In several entities, its expression was linked
to tumor dissemination and poor prognosis [20, 24, 25].
CXCR4expressioncanbeincreasedasaresultofintracellular
second messengers such as calcium [26] and cyclic AMP [27,
28] by the inactivation of the tumor suppressor gene p53 and
overexpression of NFκB [29–31], by cytokines like IL-2, IL-
10, or TGF-1β [26, 32] and by growth factors such as VEGF
and EGF [33, 34]. In addition, Staller and colleagues could
demonstrate that CXCR4 is a hypoxia inducible gene with a
HIF-1α binding domain, and that its overexpression in clear-
cell renal cell carcinoma is due to a loss-of-function of the
von Hippel-Lindau (VHL) tumor suppressor protein, which
under normoxic conditions directs HIF-1α to ubiquitin-
mediated degradation [35]. Loss of VHL stabilizes HIF-1α
leading to increased expression of hypoxia-response genes
including VEGFA, CXCR4, its ligand SDF1α,a n dHIF-1α
itself [36, 37]. They also reported a positive correlation
between strong CXCR4 expression and poor tumor-speciﬁc
survival independent of tumor stage and diﬀerentiation
grade. The latter is in contrast to the results obtained in our
study.
We analyzed the expression proﬁle of CXCR4i nas e r i e s
of human renal cell carcinoma cell lines and 113 patients’
samples for which exact tumor staging and followup data
were available and correlated the expression proﬁle with
clinicopathological data. The human renal cell carcinoma
tumor samples that are analyzed revealed varying intensities
of CXCR4 expression ranging from weak to strong, as
previously described for pancreatic and colorectal cancer
[38]. Interestingly, CXCR4 expression was downregulated
in 34% and upregulated in 24% of renal cell carcinoma as
compared to original tubuli cells. 42% of cancers revealed
the identical expression intensity of CXCR4 as tubuli cells. A
cytoplasmatic staining of CXCR4 was observed in all cancers,
whereas fewer cases depicted an additional membranous
localization of CXCR4. These observations are in line with
a recently published study by Zagzag and coworkers [44].
Furthermore, it was reported that CXCR4 surface expression
was higher in permanent cell lines than in primary tumor
samples [39]. Noteworthy, an inducible translocation of
CXCR4 from the cytoplasm to the membrane has been
reported previously in [29]. In addition, at least in breast
cancer cells, inhibited CXCR4 ubiquitination was described
as another mechanism contributing to increased CXCR4
surface levels [40].
In our renal cell carcinoma patients, a strong CXCR4
expression was signiﬁcantly associated as well with pro-
gressed cancer as indicated by the T-status as with dedif-
ferentiation. Our results are furthermore in line with recent
reportsfromourgroupandothers,describingasimilareﬀect
of CXCR4 on disease progression in other tumor entities [17,
41]. Hence, our data suggest a relevant inﬂuence of CXCR4
on proliferation and diﬀerentiation of renal cell carcinoma
with regard to the in vivo situation. This hypothesis is
strengthened by observations in a murine model, where4 Journal of Oncology
Table 1: Patient and tumor characteristics dependent on intensity of CXCR4 expression.
CXCR4 expression Statistics
Weak Medium Strong
Total number 39 (34%) 47 (42%) 27 (24%)
Average age (years) 63.8 66.3 n.s.
Gender
Female 36 (42%) 8 (30%) n.s.
Male 50 (58%) 19 (70%)
Grading
1/2 65 (78%) 11 (41%) P = .0005
3/4 18 (22%) 15 (59%)
T-status
1/2 64 (76%) 15 (56%) P = .039
3/4 20 (24%) 12 (44%)
Average size (cm) 5.7 6.0 n.s.
Survival (months) 29.7 36.8 n.s.
Average creatinin (mg/dl) 1.11 1.07 n.s.
Average hemoglobin (g/dl) 14.32 13.25 P = .019 (1-sided)
P = .039 (2-sided)
Average thrombocytes (/nl) 271 313 P = .089 (1-sided)
P = .18 (2-sided)
the metastatic capability of CXCR4-expressing RCC cells
strongly correlated with CXCR4p r o t e i nl e v e lo nc a n c e rc e l l s
and the SDF-1α expression in the target organs [23]. There-
fore, CXCR4-expressing cancer cells are certainly attracted to
the typical “homing organs” such as lungs, bone marrow,
liver, and lymph-nodes showing a high SDF-1α expression
[13, 42]. A pathophysiological relevant fact worthwhile to
be mentioned is that endothelial cells coexpress SDF-1α
and VCAM-1, thus mediating tumor-cell/endothelial cell
attachment. CXCR4a c t i v a t i o nb ySDF-1α induces β-integrin
expression, binding VCAM-1 on endothelial cell [43, 44].
Similar pathophysiological processes must be proposed for
renal cell carcinoma dissemination.
Therefore, CXCR4 might be an interesting therapeutic
target in a multimodal therapy of renal clear cell carcinoma.
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